The Michael J. Fox Foundation will pay USD 6.5 million for Nightingale Health to analyse 60,000 UK Biobank samples for neurodegeneration markers. The company disclosed the agreement as inside information on 30 September. A day later, Nightingale published an annual report setting a revenue target of at least EUR 10 million for the current financial year.

The work will use Alamar Biosciences' NULISAseq™ Neuro 220 Panel, which is designed for neurodegeneration and other brain health conditions. At the Foundation's direction, the dataset goes to UK Biobank and opens to the wider research community in 2027. The aim is to find blood markers that change years before the symptoms of Alzheimer's and Parkinson's appear.

CEO and founder Teemu Suna said the company believes the deal will produce the world's largest brain health-focused proteomics study on a single research cohort.

The contract puts Nightingale's move into proteomics to work

The annual report says Nightingale expanded its offering into proteomics in response to growing interest in multiomics, strengthening its position in the research market. The step came through its November 2025 partnership with Alamar.

The report describes research as a separate business with its own customers and products. It is also where much of the evidence for Nightingale's healthcare business comes from, including measurements of all roughly 500,000 UK Biobank participants. The largest research agreements the report lists for the past financial year were with Aalborg University, at about EUR 2.4 million, and the Moli-sani study, at about EUR 0.7 million.

Revenue follows the samples, and the first read comes in March

Nightingale's revenue for the financial year ended June 2026 was EUR 5.50 million, up from EUR 4.69 million. That fell short of the more than 50% growth the company had targeted. In June, Nightingale warned that a EUR 2.4 million project announced in September 2025 had been delayed for reasons outside its control. As a result, about EUR 2 million of revenue moves into the current financial year. Suna called it "timing, not lost business".

The company recognises revenue over time as samples are analysed. It collects advance payments for most of its services, and the gap between payment and analysis is typically three to six months. The release gives no timeline for analysing the 60,000 samples.

The company expects its liquid funds of EUR 36.8 million to last until the end of the 2027/2028 financial year. The half-year report on 9 March 2027 will be the first chance to see how much of the delayed project and the Fox Foundation contract has turned into revenue towards the EUR 10 million target.

|

|

Business

Nightingale Health's USD 6.5 million brain health deal lands as it targets EUR 10 million in revenue

·

2 min read

·

Market Signals

The Michael J. Fox Foundation will pay USD 6.5 million for Nightingale Health to analyse 60,000 UK Biobank samples for neurodegeneration markers. The company disclosed the agreement as inside information on 30 September. A day later, Nightingale published an annual report setting a revenue target of at least EUR 10 million for the current financial year.

Explore and follow profiles from this article to get timely updates:

Credit: Nightingale Health

Credit: Nightingale Health

The work will use Alamar Biosciences' NULISAseq™ Neuro 220 Panel, which is designed for neurodegeneration and other brain health conditions. At the Foundation's direction, the dataset goes to UK Biobank and opens to the wider research community in 2027. The aim is to find blood markers that change years before the symptoms of Alzheimer's and Parkinson's appear.

CEO and founder Teemu Suna said the company believes the deal will produce the world's largest brain health-focused proteomics study on a single research cohort.

The contract puts Nightingale's move into proteomics to work

The annual report says Nightingale expanded its offering into proteomics in response to growing interest in multiomics, strengthening its position in the research market. The step came through its November 2025 partnership with Alamar.

The report describes research as a separate business with its own customers and products. It is also where much of the evidence for Nightingale's healthcare business comes from, including measurements of all roughly 500,000 UK Biobank participants. The largest research agreements the report lists for the past financial year were with Aalborg University, at about EUR 2.4 million, and the Moli-sani study, at about EUR 0.7 million.

Stay sharp on Finnish market in just two minutes a day.

The previous day's top signals across Finnish-listed companies: results, deals, board and leadership moves. Fast, factual, no noise.

Delivered from Monday to Friday, first thing.

By signing up, you agree to our Privacy Policy

Stay sharp on Finnish market in just two minutes a day.

The previous day's top signals across Finnish-listed companies: results, deals, board and leadership moves. Fast, factual, no noise.

Delivered from Monday to Friday, first thing.

By signing up, you agree to our Privacy Policy

Revenue follows the samples, and the first read comes in March

Nightingale's revenue for the financial year ended June 2026 was EUR 5.50 million, up from EUR 4.69 million. That fell short of the more than 50% growth the company had targeted. In June, Nightingale warned that a EUR 2.4 million project announced in September 2025 had been delayed for reasons outside its control. As a result, about EUR 2 million of revenue moves into the current financial year. Suna called it "timing, not lost business".

The company recognises revenue over time as samples are analysed. It collects advance payments for most of its services, and the gap between payment and analysis is typically three to six months. The release gives no timeline for analysing the 60,000 samples.

The company expects its liquid funds of EUR 36.8 million to last until the end of the 2027/2028 financial year. The half-year report on 9 March 2027 will be the first chance to see how much of the delayed project and the Fox Foundation contract has turned into revenue towards the EUR 10 million target.

Nordic Listed Leaders Board Programme

Learn board work from
the people who do it.

Harvard cases, coaching and open dialogue with people who sit on and work with boards of Finnish publicly listed companies.

Next cohort

19 November 2026

Then January, April, August and October 2027

Nordic Listed Leaders Board Programme

Learn board work from
the people who do it.

Harvard cases, coaching and open dialogue with people who sit on and work with boards of Finnish publicly listed companies.

Next cohort

19 November 2026

Then January, April, August and October 2027

Topics

# Topics

Authors

Analyst

Devdatta Temgire is a data and business analyst at Listeds. He contributes research, data analysis, and pattern detection to the publication’s coverage of Nordic-listed companies, with a focus on board composition, leadership transitions, and financials. He holds an honors degree in artificial intelligence and data science alongside a bachelor’s in computer engineering, and previously worked at KPMG.

Analyst

Devdatta Temgire is a data and business analyst at Listeds. He contributes research, data analysis, and pattern detection to the publication’s coverage of Nordic-listed companies, with a focus on board composition, leadership transitions, and financials. He holds an honors degree in artificial intelligence and data science alongside a bachelor’s in computer engineering, and previously worked at KPMG.

Authors

Analyst

Devdatta Temgire is a data and business analyst at Listeds. He contributes research, data analysis, and pattern detection to the publication’s coverage of Nordic-listed companies, with a focus on board composition, leadership transitions, and financials. He holds an honors degree in artificial intelligence and data science alongside a bachelor’s in computer engineering, and previously worked at KPMG.

All Listeds newsletters (bundle)

One sign-up, the full picture.

Get every Listeds newsletter: the daily signal drumbeat, the weekly Pulse briefing, the monthly Best of the Month, the CEO letter, and the Weekend read.

By signing up, you agree to our Privacy Policy

All Listeds newsletters (bundle)

One sign-up, the full picture.

Get every Listeds newsletter: the daily signal drumbeat, the weekly Pulse briefing, the monthly Best of the Month, the CEO letter, and the Weekend read.

By signing up, you agree to our Privacy Policy

Latest signalsLive feed
Moves trackerLive feed

Nordic Listed Leaders Board Programme

Learn board work from
the people who do it.

Harvard cases, coaching and open dialogue with people who sit on and work with boards of Finnish publicly listed companies.

Next cohort

19 November 2026

Then January, April, August and October 2027

Join our Pulse, Best-of-the-Week, and Weekend newsletters

Join our Pulse, Best-of-the-Week, and Weekend newsletters